company background image
UMED logo

Unité de Fabrication des Médicaments BVMT:UMED Stock Report

Last Price

د.ت6.45

Market Cap

د.ت206.4m

7D

-3.7%

1Y

-15.8%

Updated

14 Jun, 2024

Data

Company Financials +

Unité de Fabrication des Médicaments S.A

BVMT:UMED Stock Report

Market Cap: د.ت206.4m

Unité de Fabrication des Médicaments S.A Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Unité de Fabrication des Médicaments
Historical stock prices
Current Share Priceد.ت6.45
52 Week Highد.ت8.28
52 Week Lowد.ت6.38
Beta0.066
1 Month Change-9.03%
3 Month Change-9.79%
1 Year Change-15.80%
3 Year Change-11.64%
5 Year Change-37.50%
Change since IPO-38.04%

Recent News & Updates

Recent updates

Shareholder Returns

UMEDTN PharmaceuticalsTN Market
7D-3.7%-2.3%0.5%
1Y-15.8%12.0%4.2%

Return vs Industry: UMED underperformed the TN Pharmaceuticals industry which returned 12% over the past year.

Return vs Market: UMED underperformed the TN Market which returned 4.2% over the past year.

Price Volatility

Is UMED's price volatile compared to industry and market?
UMED volatility
UMED Average Weekly Movement2.2%
Pharmaceuticals Industry Average Movement3.9%
Market Average Movement3.2%
10% most volatile stocks in TN Market4.9%
10% least volatile stocks in TN Market2.1%

Stable Share Price: UMED has not had significant price volatility in the past 3 months.

Volatility Over Time: UMED's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1989n/aRidha Charfeddinewww.unimed.com.tn

Unité de Fabrication des Médicaments S.A. develops, manufactures, markets, and sells generic medicines under the UNIMED brand in Tunisia, Africa, Asia, and Europe. The company offers Opthalmic, ENT, and inhalation solutions, infusion solutions, injectable fluids and penicillin, and cephalosporin powders, as well as vaigtaine products in approximately 40 presentations for various therapeutic classes. It manufactures medicines for third party laboratories principals.

Unité de Fabrication des Médicaments S.A Fundamentals Summary

How do Unité de Fabrication des Médicaments's earnings and revenue compare to its market cap?
UMED fundamental statistics
Market capد.ت206.40m
Earnings (TTM)د.ت13.12m
Revenue (TTM)د.ت115.13m

15.7x

P/E Ratio

1.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UMED income statement (TTM)
Revenueد.ت115.13m
Cost of Revenueد.ت55.01m
Gross Profitد.ت60.13m
Other Expensesد.ت47.01m
Earningsد.ت13.12m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.41
Gross Margin52.22%
Net Profit Margin11.39%
Debt/Equity Ratio53.0%

How did UMED perform over the long term?

See historical performance and comparison

Dividends

7.3%

Current Dividend Yield

114%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.